• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Cleerly raises $223M for AI-based software to spot atherosclerosis

Cleerly raises $223M for AI-based software to spot atherosclerosis

July 25, 2022 By Sean Whooley

cleerlyCleerly announced today that it closed an oversubscribed Series C financing round with proceeds of $223 million.

New York-based Cleerly has now raised $279 million in total, including its Series B round in 2021.

The company develops an AI-enabled approach for evaluating coronary computed tomography (CT) angiograms, allowing physicians to more easily identify, characterize and qualify atherosclerosis (plaque) build-up in the walls of the heart arteries. The information provided by Cleerly’s technology promotes a more accurate understanding of a patient’s risk of heart attack, shifting away from the way heart disease has previously been assessed through indirect surrogate markers of disease.

“At Cleerly, we are passionate about our mission to create a new standard of care for heart disease,” Cleerly CEO and founder Dr. James Min said in a news release. “We are grateful for this round of financing that will further enable our work and believe it provides a resounding vote of confidence in our vision for the future of cardiovascular care. The status quo for heart health simply isn’t good enough — for patients, providers, or payors — and our proven approach to examining for early signs of heart disease through the build-up of arterial plaque promises to deliver the change we need right now.”

Funds and accounts advised by T. Rowe Price Associates and T. Rowe Price Investment Management, as well as Fidelity Management and Research Company, led the funding round. Additional investors, including Sands Capital, Piper Sandler’s Merchant Banking and Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Breyer Capital, and Novartis participated.

Existing investors also joined in the funding round, including Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures and DigiTx Partners.

The funds will be used to enable Cleerly to expand its team and commercial reach to broaden patient and physician access to its technology-enabled care pathway across disease prevention, ranging from early diagnosis of heart disease to ensuring that ongoing treatments are effective.

Additionally, the company intends to invest in large-scale outcomes research to establish its technology as the standard of care for supporting physicians through personalized evaluation and treatment of heart disease.

This post was updated after Cleerly updated its Series C fundraise from $192 million to $223 million.

Filed Under: Business/Financial News, Cardiovascular, Digital Health, Featured, Funding Roundup, Health Technology, Imaging, News Well, Software / IT Tagged With: Cleerly

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy